Infant outcomes after maternal antiretroviral exposure in resource-limited settings

Pediatrics

Volumn 129, Issue 6, 2012, Pages

  Nielsen Saines, Karin ^a   Komarow, Lauren ^b   Cu Uvin, Susan ^c   Jourdain, Gonzague ^d   Klingman, Karin L ^e   Shapiro, David E ^b   Mofenson, Lynne ^f   Moran, Laura ^g   Campbell, Thomas B ^h   Hitti, Jane ⁱ   Fiscus, Susan ^j   Currier, Judith ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BROWN UNIVERSITY   (United States)

^d Institute of research for development Thailand   (Thailand)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

A5190; ARV toxicities; HIV; Infant safety; Maternal ARV exposure; MTCT; P1054

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICA; ANEMIA; ARTICLE; BODY HEIGHT; BRAZIL; CHILD; CHILD CARE; COHORT ANALYSIS; CONGENITAL MALFORMATION; DEVELOPING COUNTRY; DISEASE FREE SURVIVAL; DISEASE SURVEILLANCE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INBORN ERROR OF METABOLISM; INDIA; INFANT; INFANT MORTALITY; INTRAUTERINE INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MATERNAL TREATMENT; MOTHER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 4 CLINICAL TRIAL (TOPIC); PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERAL INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THAILAND; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84861918643     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2340     Document Type: Article

References (21)

1. World Health Organization. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. November, 2009. Available at: www.who.int/hiv/pub/mtct/advice/en/. Accessed May 29, 2011
2. Dorenbaum A, Cunningham CK, Gelber RD, et al International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288(2):189-198 (Pubitemid 34755279)
3. Thomas TK, Masaba R, Borkowf CB, et al; KiBS Study Team. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding - the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8(3):e1001015
4. Lallemant M, Jourdain G, Le Coeur S, et al Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217-228
5. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breastfeeding. Pediatr Infect Dis J. 2009;28(6):483-487
6. Campbell T, Smeaton I, Kumnarasmay N, et al. Efficacy and safety of EFV with either coformulated 3tC/ZDV or FTC/TDF for initial treatment of HIV-1 infected men and women in diverse multinational settings: ACTG PEARLS Study. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 27-March 2, 2011. Abstract 149LB
7. Lockman S, Hughes MD, McIntyre J, et al; OCTANE A5208 Study Team. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363(16):1499-1509
8. Cohen MS, Chen YC, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy: Results from HPTN 052. N Engl J Med. 2011;365(6):493-505
9. McMahon D, Noel F, Zheng L, et al. Suppression of nevirapine resistance with 7- vs. 21-day antiretroviral regimens after single dose nevirapine: results of A5207. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 27-March 2, 2011. Abstract T-135
10. Van Dyke R, Jourdain G, Shapiro D, et al. A Phase II study of the incidence of nevirapine (NVP) resistance mutations in HIV-infected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ddI or ZDV/ddI/LPV/r. In: Proceedings from the 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; February 8-11, 2009. Abstract T-1003
11. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis. 2010;50(3):437-444
12. Espo M, Kulmala T, Maleta K, Cullinan T, Salin ML, Ashorn P. Determinants of linear growth and predictors of severe stunting during infancy in rural Malawi. Acta Paediatr. 2002;91(12):1364-1370 (Pubitemid 36174063)
13. Fawzy A, Arpadi S, Kankasa C, et al. Early weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia. J Infect Dis. 2011;203(9):1222-1230
14. Palombi L, Buonomo E, Scarcella P, et al. Provision of highly active antiretroviral therapy (HAART) to mothers while breastfeeding and nutritional supplementation during the weaning process favorably impacts infant growth and survival in African HIV-exposed infants. In: Proceedings of the 5TH IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009. Abstract TUPEC044
15. Chilongozi D, Wang L, Brown L, et al HIVNET 024 Study Team. Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J. 2008;27(9):808-814
16. Marinda E, Humphrey JH, Iliff PJ, et al ZVITAMBO Study Group. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26(6):519-526 (Pubitemid 46847314)
17. Marazzi MC, Liotta G, Nielsen-Saines K, et al. Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. [Epub ahead of print] AIDS. 2010;24(18):2819-2826
18. Calvet GA, João E, Nielsen-Saines K, et al. Trends in characteristics and management of HIV-infected pregnant women over a nineyear period: a prospective cohort study in Rio de Janeiro, Brazil. Revista Brasileira de Epidemiologia. 2007;10(3):323-337
19. Joao EC, Calvet GA, Krauss MR, et al NISDI Perinatal Study Group. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr. 2010;53(2):176-185
20. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863-1870 (Pubitemid 34603030)
21. Goodman A, Schorge J, Greene MF. The long-term effects of in utero exposures: the DES story. N Engl J Med. 2011;364(22):2083-2084.